Choosing a Medicine Name: Getting an Invented Name Past the EMA Name Review Group

An invented name is the first thing a prescriber, pharmacist and patient will see, and it is also a patient-safety question. For centrally authorised medicines, the EMA Name Review Group assesses every proposed name, and a rejected name late in the procedure can put a launch timetable under pressure.

Who decides, and on what basis

The Name Review Group (NRG) is a CHMP group with Member State representatives, chaired by the Agency. Its task is to judge whether a proposed name could create a public-health concern or safety risk. The governing text is the CHMP Guideline on the acceptability of names for human medicinal products processed through the centralised procedure (EMA/CHMP/287710/2014), currently Revision 7, which replaced Revision 6 with effect from 1 January 2024.

What the guideline tests

  • Confusion risk: the name must not be liable to be mistaken in print, handwriting or speech for another product, taking into account indication, patient population, prescribers, form, route, strength and setting of use.
  • INN similarity: parts and stems of International Nonproprietary Names are protected, and the NRG applies a 50% similarity rule.
  • Misleading connotations: names must not suggest a therapeutic effect, composition, pharmaceutical form or route of administration, and must not be promotional.
  • Language: a name must not be offensive or inappropriate in any official EU/EEA language, and pronunciation across languages is considered.
  • Form: no symbols, dose designations, medical abbreviations or punctuation, and names may not consist wholly of an acronym or code number.

Timing and practicalities

Applicants may submit a proposed name at the earliest 18 months before the planned MAA submission, with the draft SmPC or product profile. Where the name request accompanies an eligibility request, review only proceeds once eligibility is confirmed. Up to two names can be accepted per application, and a maximum of two can be considered per NRG meeting. An accepted name is valid for three years from CHMP adoption, extendable once by one year on request.

The NRG also checks against authorised, suspended and revoked or withdrawn names in the Member States. A withdrawn product is generally treated as a risk until about five years after its authorisation became invalid, unless an expired sales-off period is justified. A common umbrella element across a company’s product names is, as a general principle, not acceptable.

Common mistakes

  • Proposing a single favourite name with no tested alternative.
  • Starting the name search only after the dossier is nearly complete.
  • Relying on a trade mark clearance alone; trade mark availability and regulatory acceptability are separate questions.
  • Overlooking sound-alike risk with products used in the same hospital or pharmacy setting.

How PQRA helps

PQRA supports sponsors in building a name strategy alongside the regulatory plan: shortlisting candidates against the guideline criteria, preparing the NRG submission with the draft product information, and aligning the timing with eligibility and MAA submission. For nationally authorised products, we also advise on how name choices fit the Greek and wider EU procedural route.

Contact PQRA to discuss your product name and your regulatory timeline.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *